Retatrutide vs Semaglutide

How does retatrutide compare with semaglutide?

These two sit at opposite ends of the same subject. Semaglutide is the most-studied incretin in existence, approved since 2017, with a placebo-controlled cardiovascular outcomes trial behind it and a decade of real-world exposure. Retatrutide is investigational, not FDA-approved and with no approval elsewhere listed in this page's sources, with the largest published weight-loss magnitudes in the class and no cardiovascular outcomes data until 2027. The comparison is not 'newer versus older' — it is 'substantiated versus promising'.

Head-to-head evidence

No head-to-head trial of retatrutide against semaglutide exists. The 24.2% and the 15% come from unrelated trials with different populations, durations and endpoints, and the retatrutide trial was smaller. This pairing is a cross-trial comparison from top to bottom.

A common mistake

Concluding that retatrutide makes semaglutide obsolete. In the only comparison that has ever been run head-to-head in this class, the newer drug's advantage was smaller than the cross-trial arithmetic had predicted.

Educational use only, never medical advice. No doses.